{"filings":[{"id":983716,"accession_number":"0001171843-26-004053","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2026-06-11T13:20:32+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Edesa Biotech announces $3.5M PIPE led by CEO; funds vitiligo program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$3.5M from sale of 729,241 common shares to healthcare-focused investors and CEO.","Investors pay $4.69/share; CEO pays $5.21/share; closing expected June 15, 2026.","Net proceeds to fund advancement of vitiligo program and drug candidate paridiprubart, plus working capital.","Company entered Registration Rights Agreement to file resale registration statement within 45 days of closing.","Securities offered under Section 4(a)(2) and Regulation D; no underwriter or placement agent used."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":872156,"accession_number":"0001171843-26-003931","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2026-06-05T13:25:18+00:00","items":["8.01"],"status":"ready","headline":"Edesa Biotech: paridiprubart shows 32% relative mortality reduction in AKI/ARDS patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exploratory Phase 3 data: paridiprubart + SOC reduced 28-day mortality to 33% vs 49% placebo (p<0.005).","MAKE30 composite endpoint incidence reduced to 41% from 53% (23% relative reduction, p<0.005).","AKI cohort of 101 severely ill patients (90% moderate-to-severe ARDS, ~50% on ventilation/ECMO).","Paridiprubart well tolerated; no significant differences in adverse events vs placebo.","Data presented at ERA Congress 2026; results exploratory and require confirmatory studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":746922,"accession_number":"0001171843-26-003793","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2026-05-29T20:15:18+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Edesa Biotech shareholders approve equity plan amendment adding 750K shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved Plan Amendment increasing shares available for issuance by 750,000 and eliminating annual per participant option grant limit.","All seven director nominees elected with over 2.6M votes for each; broker non-votes of ~2.15M on each.","Advisory vote on executive compensation approved with 2.67M for, 69K against.","Appointment of MNP LLP as auditors for FY2026 approved with 4.81M for.","Approximately 55% of outstanding shares (4.9M shares) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":453556,"accession_number":"0001171843-26-003459","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2026-05-15T13:08:56+00:00","items":["5.02"],"status":"ready","headline":"Edesa Biotech CEO to receive 90% of salary as RSUs, up from 50%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Pardeep Nijhawan will receive 90% of monthly base salary as fully vested RSUs, effective May 13, 2026.","Previously, 50% of base salary was issued as RSUs; remaining 10% paid in cash for withholding and tax requirements.","RSUs granted each month at month-end fair market value under the 2019 Equity Incentive Compensation Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443876,"accession_number":"0001171843-26-003429","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2026-05-14T20:40:19+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech Q2 net loss widens to $4.2M; progresses EB06 vitiligo Phase 2 prep","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.2M ($0.49/sh) for Q2 FY2026 vs $1.6M ($0.30/sh) in prior year.","Operating expenses rose $2.7M to $4.3M on $2.3M R&D increase for EB06 and paridiprubart prep.","Cash and cash equivalents $10.0M; working capital $8.2M as of March 31, 2026.","EB06 Phase 2 vitiligo study on track; site activations and recruitment expected mid-2026 subject to approval.","Paridiprubart Phase 3 ARDS data showed consistent treatment benefits across disease subgroups and comorbidities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105252,"accession_number":"0001171843-26-001046","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Edesa Biotech reports Phase 3 paridiprubart cut 28-day mortality by 27% (p<0.001); 278-patient study positive","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paridiprubart reduced adjusted 28-day mortality to 24% from 33% (27% relative risk reduction; p<0.001) in full 278-patient population.","Consistent benefit across severity groups: 35% reduction in non-IMV (n=174) and across comorbidities (sepsis, AKI, pneumonia).","Safety profile favorable; adverse events low and similar to placebo; over 400 patients now exposed.","Company filed provisional patent applications for paridiprubart in sepsis, acute kidney injury, and pneumonia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105251,"accession_number":"0001171843-26-000810","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech Q1 FY2026 net loss $2.2M; progresses EB06 vitiligo Phase 2 prep","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.2M ($0.28/share) vs. $1.6M ($0.48/share) a year ago; operating expenses $2.3M.","Cash and equivalents $12.1M; working capital $12.0M at Dec 31, 2025.","EB06 (anti-CXCL10) manufacturing underway for Phase 2 vitiligo study; patient enrollment targeted mid-2026.","Paridiprubart Phase 3 ARDS data under subgroup analysis; plans to present at scientific conferences.","Participating in GVFS, BIO Europe Spring, ATS 2026 and other conferences March-May 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121504,"accession_number":"0001171843-25-007918","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Edesa Biotech increases ATM offering capacity to $2.26M; discloses prior sales of $3.72M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prospectus supplement filed to increase max aggregate offering under ATM to $2,262,508.","Prior sales: $3.72M under Sept 2025 prospectus and $837K under Oct 2024 supplement.","Legal opinion of Fasken Martineau DuMoulin LLP regarding validity of shares attached."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121503,"accession_number":"0001171843-25-007913","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa reports FY2025 net loss $7.2M; Phase 3 paridiprubart meets endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.2M ($1.27/share) vs $6.2M ($1.93/share) prior year; OpEx $7.9M.","Cash $10.8M at Sept 30, 2025; raised $3.4M net from ATM post-year-end.","Phase 3 paridiprubart met primary/secondary endpoints; exploring partnerships.","Initiated manufacturing for Phase 2 EB06 vitiligo study; recruitment mid-2026.","Canadian gov't funding extended for respiratory program; JP Morgan meetings planned Jan 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121502,"accession_number":"0001171843-25-006690","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Edesa Biotech reports positive Phase 3 results for paridiprubart in ARDS; 28-day mortality reduced 13% absolute","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paridiprubart + SOC reduced 28-day mortality to 39% vs 52% placebo (n=104; p<0.001): 13% absolute improvement, 25% relative risk reduction.","Durable survival benefit at 60 days: 46% vs 59% mortality (p=0.003); 13% absolute improvement, 22% relative risk reduction.","Paridiprubart arm showed 41% higher relative rate of clinical improvement (≥2-point WCSS improvement at Day 28; p=0.032).","Safety data from >275 subjects: paridiprubart generally well-tolerated, consistent with prior profile.","Paridiprubart also in U.S. government 'Just Breathe' study; program funded by Government of Canada's Strategic Innovation Fund."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138186,"accession_number":"0001171843-25-006188","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Edesa Biotech amends CAD$23M gov't agreement, extends timeline to Dec 2028, shifts EB05 focus to general ARDS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Project completion extended to December 31, 2028 (from December 31, 2025); agreement expiration extended to later of Dec 2045 or last repayment.","First annual repayment due in 2032 (from 2029) and only if the Company earns gross revenue.","Clinical focus for EB05 changed to general ARDS from COVID-19 induced ARDS; company gains access to fully funded US government platform study.","Amendment adds reporting requirements on similar EB05 development projects and updates milestones/timelines.","Government of Canada committed up to CAD$23M ($17M USD) in partially repayable funding under original agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138185,"accession_number":"0001171843-25-005800","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Edesa Biotech files prospectus supplement for up to $4.0M ATM offering through H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM offering for up to $4,006,544 of common shares through H.C. Wainwright.","Previously sold $837,134 under existing ATM agreement from October 2024.","New shelf registration statement (S-3, File No. 333-288966) declared effective September 9, 2025.","Legal opinion from Fasken Martineau DuMoulin LLP on share validity included as exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138184,"accession_number":"0001171843-25-005235","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech reports Q3 net loss of $1.7M; advances EB06 manufacturing for vitiligo Phase 2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.7M ($0.25/sh) for quarter ended June 30, 2025, unchanged from $1.7M ($0.52/sh) YoY.","Operating expenses flat at $1.9M; R&D $0.9M, G&A $1.0M.","Cash and cash equivalents $12.4M, working capital $12.1M at June 30, 2025.","EB06 Phase 2 vitiligo IND data submission to FDA planned by end of calendar 2025; manufacturing activities ongoing.","EB05 program benefits from fully funded U.S. government platform study; first randomizations completed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155616,"accession_number":"0001171843-25-003495","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Edesa Biotech shareholders approve 1.725M share increase to 2019 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2019 Equity Incentive Compensation Plan increasing share reserve by 1,725,000 shares.","Fungible share pool provisions removed; incentive stock option limit raised from 171,429 to 300,000 shares.","All seven director nominees elected: Chypyha, Liu, MacDonald, Marshall, Nijhawan, Olson, Sistilli.","Advisory vote on executive compensation approved with 2,215,325 for, 178,016 against.","MNP LLP appointed as independent auditor for fiscal year ending September 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155615,"accession_number":"0001171843-25-003183","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech reports Q2 net loss of $1.6M; advances vitiligo drug EB06 to Phase 2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.6M ($0.30/share) vs $1.9M ($0.58) in prior-year Q2; operating expenses fell to $1.6M.","Completed $15M equity financing from institutional investors; cash and equivalents total $13.9M.","EB06 Phase 2 IND submission to FDA expected H2 2025; topline results 12-18 months after clearance.","EB05 ARDS study fully funded by government; R&D spend shifted from EB05 to EB06 program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155614,"accession_number":"0001171843-25-002027","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Edesa Biotech appoints Peter Weiler as CFO effective May 1, 2025, replacing Stephen Lemieux","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Lemieux resigns as CFO effective May 1, 2025, to pursue other opportunities; will continue as a senior financial advisor under a consulting agreement.","Peter J. Weiler appointed CFO effective May 1, 2025; base salary of $300,000 USD per annum, target annual bonus of 40% of base salary, and $2,000/month auto allowance.","Weiler previously served as President of Exzell Pharma, Inc., and held business development roles at Biosyent Inc. and Cipher Pharmaceuticals Inc.","If terminated without cause, Weiler receives 12-24 months base salary plus benefits; enhanced change-of-control severance of 24 months base salary.","Lemieux's departure not due to any disagreement with Edesa; transition is planned and orderly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174112,"accession_number":"0001171843-25-000864","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech reports Q1 FY2025 net loss of $1.6M; raises $15M in private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.6M ($0.48/share) compared to $1.7M ($0.54/share) in prior year quarter.","R&D expenses rose to $1.0M (from $0.7M) on increased manufacturing costs for paridiprubart.","Cash at Dec 31, 2024 was $1.6M; subsequent $15M preferred/common private placement closed.","Company plans IND for EB06 (anti-CXCL10) in vitiligo Phase 2; FDA submission mid-2025.","EB05 (paridiprubart) ARDS study fully funded by U.S. government; top-line vitiligo data expected within 12-18 months post clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174111,"accession_number":"0001171843-25-000796","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["1.01","5.03","3.02","3.03","5.02","8.01","9.01"],"status":"ready","headline":"Edesa Biotech announces $15M private placement led by Velan Capital; appoints David Liu to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $15M from sale of Series B-1 convertible preferred shares ($10K each) and 3.47M common shares at $1.92/share.","Proceeds to fund Phase 2 study of EB06 (CXCL10 antibody) for nonsegmental vitiligo and for working capital.","Velan Capital led placement; officers/directors purchased ~$1.1M of securities.","David Liu, Senior Analyst at Velan Capital, appointed to Board of Directors effective immediately.","Company to file resale registration statement within 30 days; beneficial ownership cap of 4.99% (or 9.99% opt-in)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191061,"accession_number":"0001171843-24-006945","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech FY2024 net loss $6.2M ($1.93/sh); cash $1.0M, negative working capital","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.2M ($1.93/sh) vs $8.4M ($2.93/sh) prior year; operating expenses down 24% to $7.0M.","Cash and equivalents $1.0M at Sep 30; negative working capital of $0.2M.","Post-year end: $1.5M from CEO-affiliated entity + $0.6M net from ATM offering.","Pivoted EB05 (paridiprubart) to U.S. govt-funded ARDS study; plans EB06 IND submission.","Topline Phase 2 EB06 results expected 12-18 months after FDA clearance; funded subject to capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191060,"accession_number":"0001171843-24-005928","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["1.01","5.03","1.02","2.03","3.02","3.03","9.01"],"status":"ready","headline":"Edesa Biotech enters $5M securities purchase agreement with CEO; $1.54M immediate investment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO-affiliated entity invests $1,540,819 for 150 Series A-1 Preferred Shares ($10K stated value) and warrants at $3.445 conversion/exercise price.","Preferred shares convertible into 435,414 common shares; warrants cover 326,560 common shares (75% of conversion shares).","Up to $5M total investment possible; purchases over $2M require shareholder approval under Canadian law.","$10M revolving credit facility with same entity terminated; no funds drawn and no termination penalties.","Securities issued in private placement exempt from registration; subject to Canadian hold periods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191059,"accession_number":"0001171843-24-005515","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Edesa Biotech enters $3.87M ATM equity facility with H.C. Wainwright; terminates prior Canaccord agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ATM agreement with H.C. Wainwright to sell up to $3.87M common shares at market prices; commission 3%.","Terminated prior equity distribution agreement with Canaccord Genuity (dated March 2023) effective Oct 3, 2024.","Under the Canaccord agreement, Edesa sold ~368,309 shares for ~$2.0M proceeds; no termination penalties.","No obligation to sell all shares under the new ATM; company may suspend sales at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207536,"accession_number":"0001171843-24-004649","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech reports Q3 net loss $1.7M; ARDS drug selected for U.S. government study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.7M ($0.52/shr) vs $2.0M ($0.68/shr) a year ago; nine-month loss $5.2M ($1.64/shr).","Cash $2.0M; working capital $0.7M; received $300K post-quarter from Canadian govt SIF fund.","EB05 (paridiprubart) chosen for HHS-funded ARDS platform study; Edesa supplies drug and tech support.","Preparing IND for Phase 2 vitiligo study of anti-CXCL10 technology in moderate-to-severe patients.","Q3 operating expenses $1.9M, down $0.2M YoY; R&D $0.9M, down $0.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224962,"accession_number":"0001654954-24-008062","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BARDA selects Edesa's paridiprubart for U.S. government-funded Phase 2 ARDS trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paridiprubart (EB05) chosen by BARDA for a randomized, double-blind, placebo-controlled Phase 2 platform trial in all-cause ARDS.","Prior Phase 2 study showed paridiprubart reduced mortality by 84% among critically ill COVID-19 ARDS patients.","Edesa's ongoing Phase 3 study of paridiprubart in COVID-19 ARDS continues in Canada and the U.S.","BARDA contract managed via PPD (Thermo Fisher); Edesa supplies drug product and technical support.","Goal is to label paridiprubart as standard-of-care for all-cause ARDS, with biomarker sub-study to inform development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224961,"accession_number":"0001654954-24-007083","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Edesa Biotech shareholders approve 67,000-share increase to equity plan, re-elect all directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected with ~818-819 thousand votes for each; 654k broker non-votes.","Advisory vote on executive compensation approved: 677,967 for, 122,761 against, 62,400 abstain.","Plan amendment increasing shares by 67,000 approved: 660,015 for, 151,395 against, 51,718 abstain.","Approximately 47% of outstanding shares (1,517,529) represented at the meeting.","MNP LLP appointed as auditors for FY ending Sept 30, 2024 with 1,463,707 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224960,"accession_number":"0001654954-24-005965","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech Q2 FY2024 net loss $1.9M ($0.58/shr); advances ARDS Phase 3 and vitiligo study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $1.9M vs $2.3M YoY; six-month loss $3.5M ($1.12/shr).","Cash $2.8M at March 31; received $0.7M post-quarter from Canadian govt funding.","Expanding Phase 3 ARDS trial with EB05; up to C$23M govt support secured.","Plans to file IND for Phase 2 pulmonary fibrosis study with EB05.","Seeks U.S. approval for Phase 2 vitiligo study; pursuing strategic deals for EB01."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244215,"accession_number":"0001654954-24-001539","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2024-02-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech reports Q1 net loss of $1.7M; secures up to C$23M govt funding for ARDS drug","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.7M ($0.54/share) vs $2.3M ($0.89) YoY; operating expenses down to $1.9M from $2.4M.","Cash and equivalents $4.3M at Dec 31, 2023; working capital $3.4M.","Secured up to C$23M from Canadian government for EB05 ARDS Phase 3; regulators approved harmonized US/Canada trial.","Planning Phase 2 for vitiligo (anti-CXCL10 mAb) and pulmonary fibrosis (EB05); seeking partnerships for dermatitis candidate EB01."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261633,"accession_number":"0001654954-23-015629","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech FY2023 net loss $8.4M ($2.93/sh); secures C$23M govt funding for Phase 3 ARDS trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $8.4M ($2.93 per share) from $17.6M ($8.37) in FY2022; R&D expenses fell to $4.8M from $13.3M.","Canadian government committed up to C$23M (partially repayable) for Phase 3 study of ARDS drug EB05 (paridiprubart); FDA Fast Track granted.","Established $10M revolving credit facility; cash and equivalents $5.4M at Sept 30, 2023, with $0.3M raised post-year-end via equity distribution.","Plans to initiate Phase 2 trial for vitiligo drug EB06 (anti-CXCL10) and file IND for fibrotic diseases; evaluating partnership for dermatitis drug EB01 after positive Phase 2b.","Management to present at Dermatology Summit and JP Morgan week in January 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261632,"accession_number":"0001654954-23-013399","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Edesa Biotech regains Nasdaq minimum bid price compliance; delisting risk removed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter confirming compliance with minimum bid price of $1.00/share after 10 consecutive business days.","Previously received deficiency notice on June 22, 2023 with compliance deadline of December 19, 2023.","Common shares (EDSA) now meet Nasdaq Capital Market listing requirement; matter closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261631,"accession_number":"0001104659-23-110653","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Edesa Biotech secures $10M revolving credit facility from CEO; $3.5M available, matures March 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving credit facility of up to $10M from Pardeep Nijhawan Medicine Professional Corp., controlled by CEO.","Initial credit limit of $3.5M; facility matures March 31, 2026 unless terminated by 90 days' notice.","Interest at CIBC US Base Rate plus 3% per annum; monthly standby fee of 1.5% on unused portion.","Repayment due within 5 business days of receiving funds from Canada's Strategic Innovation Fund (SIF).","Borrowing base tied to eligible SIF grant and license fee receivables; 85% advance rate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261630,"accession_number":"0001104659-23-108762","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2023-10-12T23:59:59+00:00","items":["1.01","2.03","7.01","8.01","9.01"],"status":"ready","headline":"Edesa Biotech secures C$23M Canadian govt funding for EB05 Phase 3 ARDS study; CEO provides $10M credit facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Government of Canada commits up to C$23M (US$17M) for Phase 3 study of EB05 (paridiprubart) in ARDS; C$5.75M non-repayable.","Remaining C$17.25M conditionally repayable starting 2029 based on revenue growth; max repayment 1.4x principal.","CEO Dr. Par Nijhawan provides $10M revolving credit facility, $3.5M immediate availability, at CIBC US Base Rate + 300bps, due March 31, 2026.","Project must be completed by Dec 31, 2025, exclusively in Canada; includes regulatory submissions and manufacturing scale-up.","Credit facility is a related-party transaction; borrowing base includes grant reimbursement and license fee receivables."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261629,"accession_number":"0001654954-23-012783","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2023-10-11T23:59:59+00:00","items":["3.03","8.01","9.01"],"status":"ready","headline":"Edesa Biotech announces 1-for-7 reverse share split effective October 11, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split reduces outstanding shares from ~21.5M to ~3.07M; no change in proportional ownership.","No fractional shares issued; fractions rounding per British Columbia law.","Adjustments made to equity awards and warrants exercise prices and shares.","Shareholder approval not required under British Columbia corporate law.","Common shares continue trading under symbol EDSA with new CUSIP 27966L306."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278849,"accession_number":"0001654954-23-010379","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech Q3 net loss narrows to $1.98M; paridiprubart study positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.98M ($0.10/sh) vs $5.79M ($0.37/sh) YoY; nine-month loss $6.65M ($0.34/sh) vs $14.74M ($1.04/sh).","Operating expenses fell to $2.06M from $5.80M in Q3; R&D down $3.52M to $1.03M due to lower clinical and manufacturing costs.","Cash $6.46M, working capital $5.39M at June 30, 2023; raised $4.63M YTD from share/warrant sales.","Positive university study data for paridiprubart (EB05) against respiratory pathogens; Phase 3 ARDS study ongoing.","Completed Phase 2b dermatitis study with favorable topline; planning vitiligo Phase 2 and systemic sclerosis Phase 2 studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297113,"accession_number":"0001654954-23-008484","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2023-06-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Edesa Biotech appoints Stephen Lemieux as CFO effective July 15, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Lemieux, CPA, appointed CFO; base salary $330K USD plus 40% target annual bonus.","Lemieux brings 20+ yrs experience; previously CFO at Titan Medical and Cipher Pharmaceuticals.","Employment agreement includes severance of 12-24 months salary and change-of-control protections.","CFO will also receive $2K monthly auto allowance and eligibility for equity awards.","Lemieux currently provides financial advisory to Edesa; appointment builds on regulatory progress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297112,"accession_number":"0001654954-23-008353","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Edesa Biotech receives Nasdaq deficiency letter for bid price below $1, has 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company has until Dec 19, 2023 to regain compliance by closing at $1 or more for 10 consecutive business days.","If not cured, may qualify for another 180-day period subject to meeting other Nasdaq standards and a reverse split.","Nasdaq listing remains fully effective; no immediate impact on trading of EDSA common shares.","Company will monitor bid price and consider options to regain compliance, but cannot assure success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297111,"accession_number":"0001654954-23-007162","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Edesa Biotech CFO to retire July 15; shareholders approve share increase for equity plan","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Kathi Niffenegger to retire effective July 15, 2023; will remain as advisor and on subsidiary board.","Shareholders approved amending 2019 Equity Incentive Plan to increase shares available by 1,380,000.","All seven director nominees elected at annual meeting with 7.06-7.26M votes each.","Advisory vote on executive compensation passed with 6.55M for, 0.55M against.","Appointment of MNP LLP as independent auditor approved with 10.23M for, 0.53M withheld."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297110,"accession_number":"0001654954-23-006222","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech Q2 net loss narrows to $2.33M; FDA agrees on Phase 3 endpoint for ARDS drug","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.33M ($0.12/share) vs $4.57M ($0.33/share) in Q2 2022; operating expenses down 47%.","Cash and equivalents $7.47M; working capital $6.56M; raised $0.60M via ATM after quarter end.","FDA agreed on primary endpoint for pivotal Phase 3 study of EB05 (paridiprubart) in ARDS patients.","Canadian regulators authorized Phase 2 study of EB06 for vitiligo; Phase 2b topline results for EB01 in ACD reported.","Plans to file IND for Phase 2 study of EB07 in systemic sclerosis (scleroderma)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317490,"accession_number":"0001104659-23-037164","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Edesa Biotech enters ATM equity distribution agreement for up to $20M (current capacity $8.37M)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $20M aggregate offering price; currently limited to ~$8.37M under S-3 rules.","Canaccord receives 3% commission; shares sold at-the-market.","Net proceeds for general corporate purposes including R&D and working capital.","Agreement dated March 27, 2023; filed as Exhibit 1.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317489,"accession_number":"0001654954-23-002689","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Edesa Biotech states no deposits or securities at Silicon Valley Bank after FDIC takeover","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company confirms no deposits or securities held at Silicon Valley Bank.","Disclosure follows FDIC takeover of SVB due to liquidity concerns.","Edesa Biotech (EDSA) provides reassurance to investors regarding bank failure exposure.","No financial impact expected from SVB collapse."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317488,"accession_number":"0001654954-23-001555","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2023-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech reports Q1 net loss of $2.33M; FDA Fast Track for ARDS drug","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $2.33M ($0.13/sh) from $4.38M ($0.33) in prior-year quarter.","Operating expenses down >50% to $2.38M; R&D decreased 66% to $1.36M.","FDA granted Fast Track designation for EB05 (ARDS) after favorable Phase 2 data.","Preliminary Phase 2b results: 1.0% EB01 cream met primary and key secondary endpoints in ACD.","Cash $8.27M; working capital $7.81M; subsequent warrant exercise raised ~$0.77M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335728,"accession_number":"0001654954-22-016606","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech reports FY2022 net loss $17.55M; cash $7.09M; Phase 2 COVID ARDS positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.55M ($1.05 loss per share) vs $13.34M ($1.10) in FY2021.","Total operating expenses decreased 22% to $18.37M from $23.68M year-over-year.","Cash and equivalents $7.09M at Sept 30, 2022; subsequent private placement raised ~$3.0M.","Phase 2 study of EB05 in COVID ARDS showed 84% reduction in risk of death vs placebo at 28 days.","Phase 2b dermatology study fully enrolled; topline data expected within 4 weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335727,"accession_number":"0001104659-22-114435","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Edesa Biotech closes $3.0M private placement priced at $1.125 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 2,691,337 common shares with warrants to purchase up to 1,345,665 shares each (12-month $1.00 and 3-year $1.50 exercise).","Gross proceeds ~$3.0M; net proceeds for Phase 2b allergic contact dermatitis study, working capital and general corporate purposes.","Officers and directors purchased $0.5 million of the securities in the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353166,"accession_number":"0001654954-22-011202","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2022-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech Q3 net loss $5.79M ($0.37/sh); Phase 3 ARDS study expanded; Phase 2b on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q3 fiscal 2022: $5.79M ($0.37/sh) vs $4.76M ($0.36/sh) in prior year; nine-month loss $14.74M ($1.04/sh).","Phase 3 ARDS study for Covid-19 expanded to second cohort; parallel recruitment underway.","Phase 2b ACD study expects to randomize all 210 subjects by Q4 2022 with topline data in early 2023.","Cash and equivalents $12.81M; working capital $9.52M at June 30, 2022.","Operating expenses for Q3 were $5.80M, down from $6.07M YoY, driven by lower G&A and share-based compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370821,"accession_number":"0001654954-22-007262","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2022-05-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Edesa Biotech holds 2022 annual meeting; all director nominees elected, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting held May 18, 2022; 6,975,601 shares (50.1%) represented.","All seven director nominees elected: Chao, Johnson, MacDonald, Nijhawan, Oakes, Pay, Sistilli.","Advisory vote on executive compensation approved: 4,105,670 for, 373,029 against.","Frequency vote chose 'every year' (4,213,160 votes); company will hold annual say-on-pay.","MNP LLP appointed as independent auditor for 2023  with 6,860,304 votes in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370820,"accession_number":"0001654954-22-006657","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2022-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech Q2 net loss $4.57M ($0.33/shr) on lower R&D spend; clinical trials advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.57M for quarter ended Mar 31, 2022 vs $2.26M year ago; R&D expenses fell $4.94M to $3.04M.","Six-month net loss $8.95M ($0.66/shr) vs $4.90M ($0.45/shr); raised ~$11.6M via ATM and direct investment.","Working capital $14.66M; cash and equivalents $15.89M at quarter end.","Phase 3 ARDS trial >25% randomized; approvals in Canada, Poland, Colombia; U.S. design discussions ongoing.","Phase 2b allergic contact dermatitis study 75% enrolled; completion expected Q4 2022, topline data early 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389868,"accession_number":"0001654954-22-003966","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2022-03-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Edesa Biotech appoints Jennifer Chao to Board; grants 30,000-share option","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jennifer Chao appointed to fill board vacancy, effective March 28, 2022; term expires at 2022 annual meeting.","Chao granted option to purchase 30,000 common shares at $2.94/share, vesting monthly over 12 months.","She will serve on the Nominating and Compensation Committees.","Chao is Managing Partner of CoreStrategies Management and serves on boards of Endo International (ENDP) and Cardiol Therapeutics (CRDL).","Over 25 years biotech/life sciences experience; former managing director at Deutsche Bank, RBC Capital Markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389867,"accession_number":"0001104659-22-037020","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2022-03-23T23:59:59+00:00","items":["1.01","1.02","3.02","9.01"],"status":"ready","headline":"Edesa Biotech raises $10M in registered direct offering at $3.65/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $10.0M from sale of 2,739,727 common shares or equivalents at $3.65/share.","Concurrent private placement of warrants to purchase 2,739,727 shares at $3.52, exercisable immediately for 5.5 years.","Offering expected to close March 24, 2022; net proceeds for working capital and general corporate purposes.","Terminated equity distribution agreement with RBC Capital Markets; $2.94M raised under that agreement through termination.","H.C. Wainwright acted as exclusive placement agent with 7% cash fee and 191,780 placement agent warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389866,"accession_number":"0001104659-22-030652","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2022-03-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Edesa Biotech grants 136,000 stock options to CEO, CFO, and President at $3.71","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Pardeep Nijhawan (CEO) granted 49,000 options; monthly vesting over 36 months, 10-year term.","Kathi Niffenegger (CFO) granted 43,500 options; Michael Brooks (President) also granted 43,500 options.","Exercise price set at $3.71 per share, equal to closing price on grant date (Feb 28, 2022).","Options vest monthly over 36 months; no immediate change in executive compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389865,"accession_number":"0001104659-22-030651","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2022-03-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Edesa Biotech amends equity distribution agreement with RBC for up to $15.4M ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended Equity Distribution Agreement with RBC Capital Markets to sell up to $15.4M additional common shares.","Previously sold 487,228 shares for $2.5M under the prior agreement.","Amendment enables ongoing at-the-market offerings through RBC as sales agent or principal.","Legal opinion from Fasken Martineau DuMoulin LLP regarding share legality attached as exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389864,"accession_number":"0001654954-22-002417","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2022-03-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Peter van der Velden resigns from Edesa Biotech board effective Feb 28, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter van der Velden resigned as director effective Feb 28, 2022; he had served since 2015.","Departure is not due to any disagreement with the company's operations, policies, or procedures.","His firm remains an investor in Edesa Biotech.","Nominating and governance committee (chaired by van der Velden) engaged a search firm to evaluate board composition and diversity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389863,"accession_number":"0001654954-22-001575","cik":1540159,"company_name":"Edesa Biotech, Inc.","ticker":"EDSA","form_type":"8-K","filed_at":"2022-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edesa Biotech reports Q1 net loss of $4.4M; Health Canada approves Phase 3 design for EB05","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.38M ($0.33/share) vs $2.64M ($0.26/share) a year ago; operating expenses up $2.55M.","R&D expenses increased $2.57M to $3.95M, primarily due to external clinical study and drug product costs.","Health Canada approved Phase 3 design of Phase 2/3 study for EB05 as rescue therapy for ARDS.","Phase 2b chronic Allergic Contact Dermatitis study reached enrollment milestone; pace returning to pre-pandemic.","Working capital $8.14M; cash $5.88M; subsequent equity issuance raised ~$1.19M from RBC Capital Markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":69446139.78920953,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-02-14T23:59:59+00:00|389863"}